Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q1 2026 results for quarter ended March 31, 2026.
Harmony Biosciences Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release attached as Exhibit 99.1 contains financial results and management commentary
Item 7.01 · Regulation FD Disclosure
- Investor presentation posted May 7, 2026, providing management’s materials for investor and analyst communications
- Exhibit 99.2 contains the substantive presentation and should be reviewed for pipeline, financial, or strategic updates
- Presentation includes forward-looking statements subject to execution risks and the company’s disclosed risk factors
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 or Securities Act Sections 11 and 12(a)(2)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Harmony Biosciences Holdings, Inc. 8-K filings
Get the next HRMY 8-K as it lands
Follow HRMY for push alerts, or ask the research agent what this filing means.